Details of the Drug Combinations

General Information of This Drug (ID: DMTI0ZO)

• Drug Name: Gilteritinib (DMTI0ZO)
• Synonyms: 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide; ASP 2215; Gilteritinib; Gilteritinib (ASP-2215); Gilteritinib (ASP2215); Gilteritinib (USAN/INN); Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Xospata

Indication

Acute myeloid leukaemia; ICD 11: 2A60; Status: Approved [1]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

12 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Cephalexin + Gilteritinib	DCV28EF	Cephalexin	Acute Myeloid Leukemia	[2]
Daunorubicin + Gilteritinib	DCCPFO9	Daunorubicin	Acute Myeloid Leukemia With FLT3/ITD Mutation	[3]
Enasidenib + Gilteritinib	DC80RE0	Enasidenib	Acute Myeloid Leukemia (AML)	[4]
Erlotinib + Gilteritinib	DCI05IV	Erlotinib	Non-Small-Cell Lung Cancer	[5]
Gilteritinib + Midazolam	DCI9R8M	Midazolam	Acute Myeloid Leukemia	[2]
Idarubicin + Gilteritinib	DC7YOJ9	Idarubicin	Acute Myeloid Leukemia	[6]
Ivosidenib + Gilteritinib	DCMA1UH	Ivosidenib	Acute Myeloid Leukemia (AML)	[4]
Venetoclax + Gilteritinib	DCGVZVC	Venetoclax	Acute Myeloid Leukemia (AML)	[7]
Voriconazole + Gilteritinib	DC2I7P5	Voriconazole	Acute Myeloid Leukemia	[2]
Daunorubicin + Gilteritinib	DCXW8J5	Daunorubicin	Acute Myeloid Leukemia	[8]
Azacitidine + Gilteritinib	DC2AUA6	Azacitidine	Acute Myeloid Leukemia (AML)	[9]
Idarubicin + Gilteritinib	DCDMZA9	Idarubicin	AML, Adult	[10]

References

• [1] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [2] ClinicalTrials.gov (NCT02014558) Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
• [3] ClinicalTrials.gov (NCT05024552) Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
• [4] ClinicalTrials.gov (NCT05756777) A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
• [5] ClinicalTrials.gov (NCT02495233) A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
• [6] ClinicalTrials.gov (NCT02236013) A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
• [7] ClinicalTrials.gov (NCT03625505) A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
• [8] ClinicalTrials.gov (NCT03836209) Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
• [9] ClinicalTrials.gov (NCT02752035) A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
• [10] ClinicalTrials.gov (NCT05177731) Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML